Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Cancer. 2014 Jul 16;120(19):2980–2985. doi: 10.1002/cncr.28744

Table 1.

Characteristics of 116 eligible patients with metastatic pancreatic cancer who were accrued on the phase II portion of the study.

Cixutumumab
Gemcitabine + Erlotinib
Gemcitabine + Erlotinib
N 57 59
Median age 63 64
Females 60% 41%
ECOG PS 0/1 (%) 40/60 45/55
Liver metastases (%) 80% 68%
Prior radical pancreatic surgery 14% 12%
Pre-existing diabetes mellitus 25% 32%